{"ticker": {"uuid": "3b1900bf-528e-409d-9d19-c15a7b8b0a69", "symbol": "STRO", "name": "Sutro Biopharma", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Sutro Biopharma, Inc. Common Stock (STRO) Stock Price Today: $26.03", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFByaWQxMHh0c19xZnJiYXJWT093eVMxNXF4N3U2MVVSbHNrM0lheWdEbGJFLWJSMHN2cno4T3h0VTZTQUdaZS1tTzB5aC1IdkRsVXlLaDJCQQ?oc=5", "source_name": "Gotrade", "published_at": "2026-07-15T03:27:52+00:00", "published_display": "15 Jul 2026 03:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary", "summary": "Sutro Biopharma presented at the TD Cowen 46th Annual Health Care Conference, highlighting its strategic transformation, leadership overhaul, and extended financial runway into Q2 2028. The company emphasized its proprietary ADC platform, which enables optimization of all compone", "url": "https://quartr.com/events/sutro-biopharma-stro-td-cowen-46th-annual-health-care-conference_FetKw8FL", "source_name": "Quartr", "published_at": "2026-07-09T21:39:43", "published_display": "09 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary", "summary": "Sutro Biopharma presented at the 2024 Wells Fargo Healthcare Conference, highlighting its focus on late-stage oncology clinical development and its proprietary antibody-drug conjugate (ADC) platform. The company's lead program, Luvelta, is in pivotal trials for ovarian cancer, pe", "url": "https://quartr.com/events/sutro-biopharma-stro-2024-wells-fargo-healthcare-conference_FetKFO7s", "source_name": "Quartr", "published_at": "2026-07-09T09:39:14", "published_display": "09 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sutro Biopharma, Inc. \u2013 NASDAQ:STRO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOTlJtWEd1cjFKb1ZHQlNXbnV3SE0wYmxWYUIxZi1vT0huT3Z5S0hGNm9Lc0UxVC00SDVtaTJEVGJvb3luYTB4bzdoRFVnTFJRQ05JMnRESlV5MjhhQURrMmtOVVVFYWVvMjVEZFgtOGNDUDhKNGdISklCRXBxdDd3elV5d3paY09QdFNtVEhmMWk3Yi05ZHE4SGZSNDg?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T03:45:18+00:00", "published_display": "08 Jul 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) price target increased by 13.85% to 37.74", "summary": "This article reports that the price target for Sutro Biopharma (STRO) has been increased by 13.85% to $37.74. No further details are provided in the given content beyond this financial adjustment.", "url": "http://www.msn.com/en-us/money/topstocks/sutro-biopharma-stro-price-target-increased-by-13-85-to-37-74/ar-AA1Zz8cz?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-05T08:41:48", "published_display": "05 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Dynamic Index", "summary": "Sutro Biopharma, Inc. (NasdaqGM: STRO) has been added to the Russell 2000 Dynamic Index, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indices for the biotechnology company, which specializes in developing oncology therapeutics ", "url": "https://www.marketscreener.com/news/sutro-biopharma-inc-nasdaqgm-stro-added-to-russell-2000-dynamic-index-ce7f5fdcdc8bf122", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T23:11:25", "published_display": "30 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (A41VMF) stock performance, financial actuals, and analyst estimates. It highlights a recent 15% increase in stock price, with analysts forecasting a wide range for future price targets. Key financial data like market cap", "url": "https://www.tradingview.com/symbols/LSX-A41VMF/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:51", "published_display": "27 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (NASDAQ: STRO) including its current stock price, market capitalization, historical performance, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering earnings per share, reven", "url": "https://www.tradingview.com/symbols/NASDAQ-STRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:51", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Sutro Biopharma, Inc. (STRO) stock, including price targets, analyst ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports. The article also", "url": "https://www.tradingview.com/symbols/NASDAQ-STRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:56", "published_display": "26 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (S090) stock performance on GETTEX, including current price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and provides information o", "url": "https://www.tradingview.com/symbols/GETTEX-S090/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:56", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Sutro Biopharma Inc (STRO), examining its price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, STRO's momentum score is 9.29, and it is suitable for range-boun", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/technical", "source_name": "TradingKey", "published_at": "2026-06-24T03:39:27", "published_display": "24 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56", "summary": "Barclays has reiterated its Buy rating on Sutro Biopharma (STRO.US) and maintained its target price of $56. This indicates continued confidence from the financial institution in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71888414/barclays-maintains-sutro-biopharma-strous-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-23T15:14:18", "published_display": "23 Jun 2026 15:14", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Sutro Biopharma Inc (STRO), highlighting its current risk score of 1.04, which ranks it 334 out of 389 in the Biotechnology & Medical Research industry. Key metrics like a beta of 1.57, volatility figures, and Sharpe Ratios are presente", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:20", "published_display": "23 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Institutional Confidence", "summary": "The article analyzes the institutional confidence in Sutro Biopharma Inc (STRO), noting a current shareholding score of 3.00, which ranks 193 out of 389 in its industry. The institutional shareholding proportion decreased by 31.45% quarter-over-quarter to 45.76%. Steven Cohen is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:37", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Sutro Biopharma Inc (STRO) has an earnings forecast score of 8.15, ranking 158th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a bullish \"Buy\" rating from most of the 14 analysts covering the stock. The company's recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T14:09:16", "published_display": "18 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis", "summary": "Sutro Biopharma Inc (STRO) has a current valuation score of 8.56, placing it 116th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.74, which is significantly below its recent high and above its recent low. However, relevant dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:16", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Sutro Biopharma Inc (STRO) has a financial score of 8.14, ranking 61st out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 16.53% year-over-year to $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:15", "published_display": "18 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This drug 'gave our daughter another chance' \u2014 now a nonprofit's deal hopes to secure its use for years to come", "summary": "Sutro Biopharma has ceased its development of a leukemia drug, but a nonprofit organization, Blood Cancer United, has taken control of the remaining supply. The drug has been crucial for patients like Aspen Peck, who was treated for a rare and aggressive form of childhood blood c", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/15/leukemia-aml-blood-cancer-united-sutro-biopharma.html", "source_name": "The Business Journals", "published_at": "2026-06-15T21:40:04", "published_display": "15 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (Nasdaq:STRO) - Stock Analysis", "summary": "Sutro Biopharma (STRO) is an oncology company with a market cap of US$500.4 million, currently 41.7% undervalued by analysts. The company faces financial risks, including negative shareholder equity, dilution, and a forecast decline in earnings, but analysts have recently increas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stro/sutro-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-15T00:10:05", "published_display": "15 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50", "summary": "Truist Financial has initiated coverage on Sutro Biopharma (STRO.US) with a Buy rating. The firm has set a price target of $50 for the company's stock. This new rating and target price indicate a positive outlook from Truist Financial on Sutro Biopharma's future performance.", "url": "https://www.moomoo.com/news/post/71396788/truist-financial-initiates-sutro-biopharma-strous-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-11T23:08:54", "published_display": "11 Jun 2026 23:08", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities", "summary": "Truist Securities has set a price target of $50.00 per share for Sutro Biopharma (NASDAQ: STRO). This new target suggests a potential upside for shareholders compared to the stock's current trading price. The adjustment reflects Truist Securities' latest assessment of Sutro Bioph", "url": "https://www.moomoo.com/news/post/71398009/sutro-biopharma-price-target-announced-at-50-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-11T13:09:40", "published_display": "11 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike", "summary": "Sutro Biopharma director James P. Panek was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly, starting July 5, 2026, and will be fully vested by June 5, 2027, or the 2027 annual stockholders meeting, ", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-d55f6ad70d8d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:39:07", "published_display": "09 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09", "summary": "SUTRO BIOPHARMA, INC. director Jon Marc Wigginton was granted 10,000 stock options at an exercise price of $26.09 per share on June 5, 2026. These options represent equity-based compensation and will vest monthly at a rate of 8.33% starting July 5, 2026, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-609fbdf852b1.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:25:07", "published_display": "09 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027", "summary": "Sutro Biopharma director Joseph M. Lobacki was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly starting July 5, 2026, and become fully vested by the company's 2027 annual shareholders meeting or June", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-c1035bc644c3.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:20:07", "published_display": "09 Jun 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000-share stock option grant", "summary": "Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. This compensation-related award vests monthly, with the first tranche starting July 5, 2026, and will be fully vested by the earlier of the", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-02d71973ccb4.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:18:07", "published_display": "09 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity", "summary": "Sutro Biopharma director Heidi Hunter was granted 10,000 stock options at an exercise price of $26.09 per share, expiring on June 5, 2036. The options vest monthly over approximately one year, commencing July 5, 2026, and are fully vested by the earlier of the 2027 annual stockho", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-d2bff5fe4623.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:16:06", "published_display": "09 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) Proxy filing Summary", "summary": "Sutro Biopharma (STRO) released a proxy filing summary for its upcoming annual meeting on June 5, 2026, which will be held virtually. Key proposals include the election of three Class II directors, the ratification of Ernst & Young LLP as auditor for 2026, and an advisory vote on", "url": "https://quartr.com/events/sutro-biopharma-stro-proxy-filing_FetKbYng", "source_name": "Quartr", "published_at": "2026-06-09T02:40:07", "published_display": "09 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results", "summary": "Sutro Biopharma, Inc. (NASDAQ: STRO) announced the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Shareholders elected three Class II directors\u2014Jane Chung, Connie Matsui, and James Panek\u2014and approved two additional proposals, including the ratification o", "url": "https://www.stocktitan.net/sec-filings/STRO/8-k-sutro-biopharma-inc-reports-material-event-e445d98b84c5.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:00:45", "published_display": "08 Jun 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STRO - Sutro Biopharma Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and analyst ratings for Sutro Biopharma Inc. (STRO). It details insider transactions, company leadership information, and a timeline of news events related to the company's clinical trials, financial r", "url": "https://finviz.com/stock?t=STRO", "source_name": "Finviz", "published_at": "2026-06-04T07:40:14", "published_display": "04 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings", "summary": "Sutro Biopharma's CFO, Gregory K. Chow, exercised 2,500 Restricted Stock Units (RSUs) on June 2, 2026, increasing his direct holdings to 4,725 shares of Common Stock and retaining 7,500 RSUs. This transaction was a compensation-related exercise with no shares sold, and tax liabil", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-82c5304652d5.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:12", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates a Buy Rating on Sutro Biopharma (STRO)", "summary": "Barclays has initiated a Buy rating on Sutro Biopharma (STRO) with a price target. This follows a recent Buy rating from H.C. Wainwright, although Bank of America Securities reiterated a Sell rating. For the quarter ending March 31, Sutro Biopharma reported $14.52 million in reve", "url": "https://www.theglobeandmail.com/investing/markets/stocks/STRO/pressreleases/2194785/barclays-initiates-a-buy-rating-on-sutro-biopharma-stro/", "source_name": "The Globe and Mail", "published_at": "2026-05-29T09:09:59", "published_display": "29 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46%", "summary": "Analysts have significantly upgraded Sutro Biopharma's revenue forecasts for the current year by 46%, now expecting US$44 million in 2026, despite a projected 56% reduction from prior sales. The consensus price target has also increased by 31% to US$46.64, driven by the improved ", "url": "https://www.sahmcapital.com/news/content/industry-analysts-just-upgraded-their-sutro-biopharma-inc-nasdaqstro-revenue-forecasts-by-46-2026-05-28", "source_name": "Sahm", "published_at": "2026-05-29T07:10:59", "published_display": "29 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/barclays-initiates-sutro-biopharma-overweight-112410843.html", "source_name": "MT Newswires", "published_at": "2026-05-28T11:24:10+00:00", "published_display": "28 May 2026 11:24", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/news-flash-analysts-just-made-111915265.html", "source_name": "Simply Wall St.", "published_at": "2026-05-28T11:19:15+00:00", "published_display": "28 May 2026 11:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates Sutro Biopharma stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQc3lmT1FsSEotMHRHTFg4VHc4SmFtNVZUWkxCWGtGd0tDUzJuTHRKTVhDTmhlTGZiVmd1S2VRcHNZWGVLWXdqQXVyblN3RE9zVm91djFxZGlsaU96NG5YM0tzYVN2VXJ5TWk1SUFoRzdJSFZfSUl4YTg1czV3a0NhTDRjS1VyT3ZjUTJuZ1VFVmEzMmxyLXkydXFlUkI5RndlcXNzZDlXOW5DWXJIX3I3Y3FYSzVISWtrdmZwVnJZRTE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQLWo4b1h5cmNJejIyT19WRTNndk1kTDVLYm9DSXd5N1YzWHJmM0lxX0pmRC1CcnBJS2NBRUhRZjg4dktyX3pzdHQ2TjFfMDN2NnpkMEdFd2lJemJOQVZhXzhVdDZaZ0VNV2lfYVh2LUhNSXMwS2UwSGRjQXVURS1JOVlXSEQzWVFaaERocGVNTUJSdw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sutro-biopharma-shares-rise-q1-185412917.html", "source_name": "MT Newswires", "published_at": "2026-05-15T18:54:12+00:00", "published_display": "15 May 2026 18:54", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-upgrades-sutro-biopharma-outperform-103359861.html", "source_name": "MT Newswires", "published_at": "2026-05-15T10:33:59+00:00", "published_display": "15 May 2026 10:33", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sutro Biopharma Q1 Loss Narrows, Revenue Declines", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sutro-biopharma-q1-loss-narrows-201711202.html", "source_name": "MT Newswires", "published_at": "2026-05-14T20:17:11+00:00", "published_display": "14 May 2026 20:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sutro-biopharma-reports-first-quarter-200500306.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-drug maker Sutro projects cash runway into 2028 as ADC pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOa0R0cEk5Q3Y0X0VBWFp3c2MwbE9nOXNZTWZnLUVDYV9JMy1OSkxkNkIwaENsR1NoYllwdU91U3BrNGNGLURuTHJmYkVPX0ZyaUxLNHpjZWREcVNHQlVxazNoMWtLNHVoMVZ5U1JlSVg5UHNyeWFmVXc3RzFWeS02bzlzRy0tbUVYTEkxRFpQNnBUdXdCTnQtbG5GQ19yVDdqWHVjVkc4d2xwVi0tUndCM1pYck9ZUzFHVHpJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ3FLMTNiLUJrcWQydVpnYnRFT2twRVJrUUNKQjE0aHRmR2xZUjRvMmtwV2dmRjZnNnJxTTFLWHM1bGdULUxlWTJBMjZmYW1zMW1hOXJHbTRvb1M0U3pFX2hqNElaaXBzVlREVXBsekVYZVdHUFQ1cThsbThWVkZhWGttb050eWstajZLbjk3TXFrSzd6bkZQOHJhSVVneTlEUzFxMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQdjJuQVNlaC1DSFl0UVdxQ2lPTUplWU1scEJfU3lwMWxhbWs4bmZuSjJ6aEpRaDVWLVd1TXpXQjQ0ZW1UR2U3Y0hTZUpDSExPZ2ZRaWZuTy0xcC1DSW5iV0c1VU45OHdCb0NqR3k0MFpFRnkwU1RBMmFuTElYd2JBWGpwVXV3OEF6ODBVenV3cFA1b2VmQV9hUkxDWWVmUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sutro's cancer drug candidate outperformed benchmark ADCs in lab models", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMFRfYWxkS0tsN2dfT0ltZWNaZTdLUFBsbnAzYlRMTzIyVGQ2OFVlOENuZjlxY09fa1Vad0J4OVpJMzQzeVJDZ1JtTzg4eUxKT2djUTFEd0c2T0pzTkxDTjJHaVVBcWoxN09PcGozeXNtVHJHQllQVFpvZmFTdnZDOUdDcm5wNG9sYVpqRzVUMnJvVzI0c2NBSExRMllzUkdvejBmUmxhbGlhUWk5Rm5OSWdRSVI0UnlL?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPUTNLTlhIU1JYZC1hRzkyaU0zTHM3YjRBTFNtNzFuRF9YZzc0VkdnV2FUckFWWmVSbF9HSG83QU40Y01mbnF3dl91RmpMdmlqU1hoQ1NwMTgzWDQyRTVMUUVESGt6U2EwSmhoMkN4RXE3V1JFQU9sank4Ym4zVWt5YThXZ2Fya2hEaDJnblE2N3Q2SkVwMnhOSw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sutro Biopharma Q3 Loss Of US$56.9 Million Tests Profitability Narratives For STRO Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro says cash lasts to 2028 as cancer drug pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRnE1T0dwSVI2X3BqaGVsTnlUUkhqeHBpRS1RWjd5VFhEUWdFUnZ2M1J2cWsxR1FJaDhQSkdyMUl1TXpFV0FpQWdUZVBXb2NITUg1dXhvNEtvMmtjMkpxTjNrT0NiWEtBcmdHVUVtcVkzWEZKVHc1RVFkODFHWFFKdFRuaWxXeGVKRW82ekxiRHUyd2cyeWZDQnVJVW9qSjBEWXFnWnBENmcybkJWQlZQUWxkZ0JnZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUlRzV293cTczb0dZZjlNTjd0YWVZSGlQNTZQanFWQzF1UEZwcC1hZmRHcGJzRWFZNWlEVE94eGY2aGxGQi1oSlRPbktHUXZPSXNUaVkweF82YUpQVkpwYUFyYmRuZ0t1M1NJVDhmdG5sR01UZkN1cVNGZlJRdlN5aUcxWUR6Z0JETXpBNGMzN1A2TTBBTzY4RTBiQUl3ZkVROTBxLUJRT0lsS2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma lines up March health-care investor talks in Boston and Miami", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWUh4N08xQ0k3bUQwUW1uQ3JFa2dPSFFPX2FnNGl4bHVuaUo2YmUzOVpqd2JzRUF0RXhYY2Z3azM2ZUp1NW8yck8teEVadnFQb25RVTNkdWUtRWRoUlZkUEtyNXhtMWJNdGZFOFh5VUE4Z21xQUJiRVdtbndsZ1JzUmQyOVN0MU9wYnZYejZzeFhLTlI2VjJvem1FNF9Ublg4TmZfUmJWQTRDUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncology company Sutro lines up $110M for research and development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPSW5JSVc0Zk1pTEdXZlpTc2RlU2xsRGFCVC10MGhwU2ZHQ1luYlZ3M2YxSkxHbURjTXZtb21mQUdlZ1pMNi1UY0llN3dHMjUzTEZqZ0g1WXlBR05XRG45TDlmOUlTd0pjOXVqLVBoVVZ0TlJpUHJDVnNISmVMS3VXbXZPUFh3aDNLYTJrWm11NXRydmZvSTVOQjlsS0hiN3haUDRNS3FJVGpPVHU3aHpnN1FFZE0zWU10M2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQMEFUNkFidk9SWUF2X0QzYUtSTF84bV8tdUJ0QkowUi1IWDVKbVp0Q3otQWo5RXA1SFJ6bkU5Z2EzMkZCYWFnN1RBZjFLVXpXdm5UaW4yQUd0T2tpa1p4M19PTlhpcDQ5Um9OWU1GMHFlbXl1R0tDN1VCUlJUYmtDQlJZdw?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Sutro Biopharma, Inc. Common Stock (STRO) Stock Price Today: $26.03", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFByaWQxMHh0c19xZnJiYXJWT093eVMxNXF4N3U2MVVSbHNrM0lheWdEbGJFLWJSMHN2cno4T3h0VTZTQUdaZS1tTzB5aC1IdkRsVXlLaDJCQQ?oc=5", "source_name": "Gotrade", "published_at": "2026-07-15T03:27:52+00:00", "published_display": "15 Jul 2026 03:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary", "summary": "Sutro Biopharma presented at the TD Cowen 46th Annual Health Care Conference, highlighting its strategic transformation, leadership overhaul, and extended financial runway into Q2 2028. The company emphasized its proprietary ADC platform, which enables optimization of all compone", "url": "https://quartr.com/events/sutro-biopharma-stro-td-cowen-46th-annual-health-care-conference_FetKw8FL", "source_name": "Quartr", "published_at": "2026-07-09T21:39:43", "published_display": "09 Jul 2026 21:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary", "summary": "Sutro Biopharma presented at the 2024 Wells Fargo Healthcare Conference, highlighting its focus on late-stage oncology clinical development and its proprietary antibody-drug conjugate (ADC) platform. The company's lead program, Luvelta, is in pivotal trials for ovarian cancer, pe", "url": "https://quartr.com/events/sutro-biopharma-stro-2024-wells-fargo-healthcare-conference_FetKFO7s", "source_name": "Quartr", "published_at": "2026-07-09T09:39:14", "published_display": "09 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Sutro Biopharma, Inc. \u2013 NASDAQ:STRO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOTlJtWEd1cjFKb1ZHQlNXbnV3SE0wYmxWYUIxZi1vT0huT3Z5S0hGNm9Lc0UxVC00SDVtaTJEVGJvb3luYTB4bzdoRFVnTFJRQ05JMnRESlV5MjhhQURrMmtOVVVFYWVvMjVEZFgtOGNDUDhKNGdISklCRXBxdDd3elV5d3paY09QdFNtVEhmMWk3Yi05ZHE4SGZSNDg?oc=5", "source_name": "TradingView", "published_at": "2026-07-08T03:45:18+00:00", "published_display": "08 Jul 2026 03:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) price target increased by 13.85% to 37.74", "summary": "This article reports that the price target for Sutro Biopharma (STRO) has been increased by 13.85% to $37.74. No further details are provided in the given content beyond this financial adjustment.", "url": "http://www.msn.com/en-us/money/topstocks/sutro-biopharma-stro-price-target-increased-by-13-85-to-37-74/ar-AA1Zz8cz?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-05T08:41:48", "published_display": "05 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Dynamic Index", "summary": "Sutro Biopharma, Inc. (NasdaqGM: STRO) has been added to the Russell 2000 Dynamic Index, as announced on June 28, 2026. This inclusion is part of a series of additions to various Russell indices for the biotechnology company, which specializes in developing oncology therapeutics ", "url": "https://www.marketscreener.com/news/sutro-biopharma-inc-nasdaqgm-stro-added-to-russell-2000-dynamic-index-ce7f5fdcdc8bf122", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T23:11:25", "published_display": "30 Jun 2026 23:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (A41VMF) stock performance, financial actuals, and analyst estimates. It highlights a recent 15% increase in stock price, with analysts forecasting a wide range for future price targets. Key financial data like market cap", "url": "https://www.tradingview.com/symbols/LSX-A41VMF/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T01:10:51", "published_display": "27 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (NASDAQ: STRO) including its current stock price, market capitalization, historical performance, and analyst forecasts. It also delves into the company's financial actuals and estimates, covering earnings per share, reven", "url": "https://www.tradingview.com/symbols/NASDAQ-STRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:10:51", "published_display": "26 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STRO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Sutro Biopharma, Inc. (STRO) stock, including price targets, analyst ratings, and financial performance data. It details the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports. The article also", "url": "https://www.tradingview.com/symbols/NASDAQ-STRO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T10:09:56", "published_display": "26 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090)", "summary": "This article provides an overview of Sutro Biopharma, Inc. (S090) stock performance on GETTEX, including current price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and provides information o", "url": "https://www.tradingview.com/symbols/GETTEX-S090/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:09:56", "published_display": "26 Jun 2026 03:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Sutro Biopharma Inc (STRO), examining its price momentum, support and resistance levels, and various technical indicators and moving averages. According to the analysis, STRO's momentum score is 9.29, and it is suitable for range-boun", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/technical", "source_name": "TradingKey", "published_at": "2026-06-24T03:39:27", "published_display": "24 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56", "summary": "Barclays has reiterated its Buy rating on Sutro Biopharma (STRO.US) and maintained its target price of $56. This indicates continued confidence from the financial institution in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71888414/barclays-maintains-sutro-biopharma-strous-with-buy-rating-maintains-target", "source_name": "Moomoo", "published_at": "2026-06-23T15:14:18", "published_display": "23 Jun 2026 15:14", "sentiment": "positive", "sentiment_pct": 91, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Sutro Biopharma Inc (STRO), highlighting its current risk score of 1.04, which ranks it 334 out of 389 in the Biotechnology & Medical Research industry. Key metrics like a beta of 1.57, volatility figures, and Sharpe Ratios are presente", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-23T06:41:20", "published_display": "23 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Institutional Confidence", "summary": "The article analyzes the institutional confidence in Sutro Biopharma Inc (STRO), noting a current shareholding score of 3.00, which ranks 193 out of 389 in its industry. The institutional shareholding proportion decreased by 31.45% quarter-over-quarter to 45.76%. Steven Cohen is ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T01:40:37", "published_display": "19 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Sutro Biopharma Inc (STRO) has an earnings forecast score of 8.15, ranking 158th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00, with a bullish \"Buy\" rating from most of the 14 analysts covering the stock. The company's recen", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T14:09:16", "published_display": "18 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis", "summary": "Sutro Biopharma Inc (STRO) has a current valuation score of 8.56, placing it 116th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -1.74, which is significantly below its recent high and above its recent low. However, relevant dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:16", "published_display": "18 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Sutro Biopharma Inc (STRO) has a financial score of 8.14, ranking 61st out of 388 in the Biotechnology & Medical Research industry, indicating a weak financial status despite high operating efficiency. The company's latest quarterly revenue decreased by 16.53% year-over-year to $", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-stro/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T10:40:15", "published_display": "18 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This drug 'gave our daughter another chance' \u2014 now a nonprofit's deal hopes to secure its use for years to come", "summary": "Sutro Biopharma has ceased its development of a leukemia drug, but a nonprofit organization, Blood Cancer United, has taken control of the remaining supply. The drug has been crucial for patients like Aspen Peck, who was treated for a rare and aggressive form of childhood blood c", "url": "https://www.bizjournals.com/sanfrancisco/news/2026/06/15/leukemia-aml-blood-cancer-united-sutro-biopharma.html", "source_name": "The Business Journals", "published_at": "2026-06-15T21:40:04", "published_display": "15 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (Nasdaq:STRO) - Stock Analysis", "summary": "Sutro Biopharma (STRO) is an oncology company with a market cap of US$500.4 million, currently 41.7% undervalued by analysts. The company faces financial risks, including negative shareholder equity, dilution, and a forecast decline in earnings, but analysts have recently increas", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-stro/sutro-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-15T00:10:05", "published_display": "15 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50", "summary": "Truist Financial has initiated coverage on Sutro Biopharma (STRO.US) with a Buy rating. The firm has set a price target of $50 for the company's stock. This new rating and target price indicate a positive outlook from Truist Financial on Sutro Biopharma's future performance.", "url": "https://www.moomoo.com/news/post/71396788/truist-financial-initiates-sutro-biopharma-strous-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-11T23:08:54", "published_display": "11 Jun 2026 23:08", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities", "summary": "Truist Securities has set a price target of $50.00 per share for Sutro Biopharma (NASDAQ: STRO). This new target suggests a potential upside for shareholders compared to the stock's current trading price. The adjustment reflects Truist Securities' latest assessment of Sutro Bioph", "url": "https://www.moomoo.com/news/post/71398009/sutro-biopharma-price-target-announced-at-50-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-11T13:09:40", "published_display": "11 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike", "summary": "Sutro Biopharma director James P. Panek was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly, starting July 5, 2026, and will be fully vested by June 5, 2027, or the 2027 annual stockholders meeting, ", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-d55f6ad70d8d.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:39:07", "published_display": "09 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09", "summary": "SUTRO BIOPHARMA, INC. director Jon Marc Wigginton was granted 10,000 stock options at an exercise price of $26.09 per share on June 5, 2026. These options represent equity-based compensation and will vest monthly at a rate of 8.33% starting July 5, 2026, contingent on his continu", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-609fbdf852b1.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:25:07", "published_display": "09 Jun 2026 20:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027", "summary": "Sutro Biopharma director Joseph M. Lobacki was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. The options will vest monthly starting July 5, 2026, and become fully vested by the company's 2027 annual shareholders meeting or June", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-c1035bc644c3.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:20:07", "published_display": "09 Jun 2026 20:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) director receives 10,000-share stock option grant", "summary": "Sutro Biopharma director Jagpal Sukhi was granted 10,000 stock options with an exercise price of $26.09 per share, expiring on June 5, 2036. This compensation-related award vests monthly, with the first tranche starting July 5, 2026, and will be fully vested by the earlier of the", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-02d71973ccb4.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:18:07", "published_display": "09 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity", "summary": "Sutro Biopharma director Heidi Hunter was granted 10,000 stock options at an exercise price of $26.09 per share, expiring on June 5, 2036. The options vest monthly over approximately one year, commencing July 5, 2026, and are fully vested by the earlier of the 2027 annual stockho", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-d2bff5fe4623.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:16:06", "published_display": "09 Jun 2026 20:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) Proxy filing Summary", "summary": "Sutro Biopharma (STRO) released a proxy filing summary for its upcoming annual meeting on June 5, 2026, which will be held virtually. Key proposals include the election of three Class II directors, the ratification of Ernst & Young LLP as auditor for 2026, and an advisory vote on", "url": "https://quartr.com/events/sutro-biopharma-stro-proxy-filing_FetKbYng", "source_name": "Quartr", "published_at": "2026-06-09T02:40:07", "published_display": "09 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results", "summary": "Sutro Biopharma, Inc. (NASDAQ: STRO) announced the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. Shareholders elected three Class II directors\u2014Jane Chung, Connie Matsui, and James Panek\u2014and approved two additional proposals, including the ratification o", "url": "https://www.stocktitan.net/sec-filings/STRO/8-k-sutro-biopharma-inc-reports-material-event-e445d98b84c5.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:00:45", "published_display": "08 Jun 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "STRO - Sutro Biopharma Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and analyst ratings for Sutro Biopharma Inc. (STRO). It details insider transactions, company leadership information, and a timeline of news events related to the company's clinical trials, financial r", "url": "https://finviz.com/stock?t=STRO", "source_name": "Finviz", "published_at": "2026-06-04T07:40:14", "published_display": "04 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings", "summary": "Sutro Biopharma's CFO, Gregory K. Chow, exercised 2,500 Restricted Stock Units (RSUs) on June 2, 2026, increasing his direct holdings to 4,725 shares of Common Stock and retaining 7,500 RSUs. This transaction was a compensation-related exercise with no shares sold, and tax liabil", "url": "https://www.stocktitan.net/sec-filings/STRO/form-4-sutro-biopharma-inc-insider-trading-activity-82c5304652d5.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:12", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates a Buy Rating on Sutro Biopharma (STRO)", "summary": "Barclays has initiated a Buy rating on Sutro Biopharma (STRO) with a price target. This follows a recent Buy rating from H.C. Wainwright, although Bank of America Securities reiterated a Sell rating. For the quarter ending March 31, Sutro Biopharma reported $14.52 million in reve", "url": "https://www.theglobeandmail.com/investing/markets/stocks/STRO/pressreleases/2194785/barclays-initiates-a-buy-rating-on-sutro-biopharma-stro/", "source_name": "The Globe and Mail", "published_at": "2026-05-29T09:09:59", "published_display": "29 May 2026 09:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Industry Analysts Just Upgraded Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts By 46%", "summary": "Analysts have significantly upgraded Sutro Biopharma's revenue forecasts for the current year by 46%, now expecting US$44 million in 2026, despite a projected 56% reduction from prior sales. The consensus price target has also increased by 31% to US$46.64, driven by the improved ", "url": "https://www.sahmcapital.com/news/content/industry-analysts-just-upgraded-their-sutro-biopharma-inc-nasdaqstro-revenue-forecasts-by-46-2026-05-28", "source_name": "Sahm", "published_at": "2026-05-29T07:10:59", "published_display": "29 May 2026 07:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/barclays-initiates-sutro-biopharma-overweight-112410843.html", "source_name": "MT Newswires", "published_at": "2026-05-28T11:24:10+00:00", "published_display": "28 May 2026 11:24", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "News Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Forecasts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/news-flash-analysts-just-made-111915265.html", "source_name": "Simply Wall St.", "published_at": "2026-05-28T11:19:15+00:00", "published_display": "28 May 2026 11:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Barclays initiates Sutro Biopharma stock with overweight rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQc3lmT1FsSEotMHRHTFg4VHc4SmFtNVZUWkxCWGtGd0tDUzJuTHRKTVhDTmhlTGZiVmd1S2VRcHNZWGVLWXdqQXVyblN3RE9zVm91djFxZGlsaU96NG5YM0tzYVN2VXJ5TWk1SUFoRzdJSFZfSUl4YTg1czV3a0NhTDRjS1VyT3ZjUTJuZ1VFVmEzMmxyLXkydXFlUkI5RndlcXNzZDlXOW5DWXJIX3I3Y3FYSzVISWtrdmZwVnJZRTE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQLWo4b1h5cmNJejIyT19WRTNndk1kTDVLYm9DSXd5N1YzWHJmM0lxX0pmRC1CcnBJS2NBRUhRZjg4dktyX3pzdHQ2TjFfMDN2NnpkMEdFd2lJemJOQVZhXzhVdDZaZ0VNV2lfYVh2LUhNSXMwS2UwSGRjQXVURS1JOVlXSEQzWVFaaERocGVNTUJSdw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Sutro Biopharma Shares Rise After Q1 Loss Narrows", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sutro-biopharma-shares-rise-q1-185412917.html", "source_name": "MT Newswires", "published_at": "2026-05-15T18:54:12+00:00", "published_display": "15 May 2026 18:54", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Upgrades Sutro Biopharma to Outperform From Neutral, Boosts Price Target to $60 From $22", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-upgrades-sutro-biopharma-outperform-103359861.html", "source_name": "MT Newswires", "published_at": "2026-05-15T10:33:59+00:00", "published_display": "15 May 2026 10:33", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Q1 Loss Narrows, Revenue Declines", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sutro-biopharma-q1-loss-narrows-201711202.html", "source_name": "MT Newswires", "published_at": "2026-05-14T20:17:11+00:00", "published_display": "14 May 2026 20:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sutro-biopharma-reports-first-quarter-200500306.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cancer-drug maker Sutro projects cash runway into 2028 as ADC pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOa0R0cEk5Q3Y0X0VBWFp3c2MwbE9nOXNZTWZnLUVDYV9JMy1OSkxkNkIwaENsR1NoYllwdU91U3BrNGNGLURuTHJmYkVPX0ZyaUxLNHpjZWREcVNHQlVxazNoMWtLNHVoMVZ5U1JlSVg5UHNyeWFmVXc3RzFWeS02bzlzRy0tbUVYTEkxRFpQNnBUdXdCTnQtbG5GQ19yVDdqWHVjVkc4d2xwVi0tUndCM1pYck9ZUzFHVHpJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma: Recycling Past Data Ahead Of The Readout, Sell", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPQ3FLMTNiLUJrcWQydVpnYnRFT2twRVJrUUNKQjE0aHRmR2xZUjRvMmtwV2dmRjZnNnJxTTFLWHM1bGdULUxlWTJBMjZmYW1zMW1hOXJHbTRvb1M0U3pFX2hqNElaaXBzVlREVXBsekVYZVdHUFQ1cThsbThWVkZhWGttb050eWstajZLbjk3TXFrSzd6bkZQOHJhSVVneTlEUzFxMA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQdjJuQVNlaC1DSFl0UVdxQ2lPTUplWU1scEJfU3lwMWxhbWs4bmZuSjJ6aEpRaDVWLVd1TXpXQjQ0ZW1UR2U3Y0hTZUpDSExPZ2ZRaWZuTy0xcC1DSW5iV0c1VU45OHdCb0NqR3k0MFpFRnkwU1RBMmFuTElYd2JBWGpwVXV3OEF6ODBVenV3cFA1b2VmQV9hUkxDWWVmUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro's cancer drug candidate outperformed benchmark ADCs in lab models", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMFRfYWxkS0tsN2dfT0ltZWNaZTdLUFBsbnAzYlRMTzIyVGQ2OFVlOENuZjlxY09fa1Vad0J4OVpJMzQzeVJDZ1JtTzg4eUxKT2djUTFEd0c2T0pzTkxDTjJHaVVBcWoxN09PcGozeXNtVHJHQllQVFpvZmFTdnZDOUdDcm5wNG9sYVpqRzVUMnJvVzI0c2NBSExRMllzUkdvejBmUmxhbGlhUWk5Rm5OSWdRSVI0UnlL?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPUTNLTlhIU1JYZC1hRzkyaU0zTHM3YjRBTFNtNzFuRF9YZzc0VkdnV2FUckFWWmVSbF9HSG83QU40Y01mbnF3dl91RmpMdmlqU1hoQ1NwMTgzWDQyRTVMUUVESGt6U2EwSmhoMkN4RXE3V1JFQU9sank4Ym4zVWt5YThXZ2Fya2hEaDJnblE2N3Q2SkVwMnhOSw?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma Q3 Loss Of US$56.9 Million Tests Profitability Narratives For STRO Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro says cash lasts to 2028 as cancer drug pipeline advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRnE1T0dwSVI2X3BqaGVsTnlUUkhqeHBpRS1RWjd5VFhEUWdFUnZ2M1J2cWsxR1FJaDhQSkdyMUl1TXpFV0FpQWdUZVBXb2NITUg1dXhvNEtvMmtjMkpxTjNrT0NiWEtBcmdHVUVtcVkzWEZKVHc1RVFkODFHWFFKdFRuaWxXeGVKRW82ekxiRHUyd2cyeWZDQnVJVW9qSjBEWXFnWnBENmcybkJWQlZQUWxkZ0JnZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026 (NASDAQ:STRO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUlRzV293cTczb0dZZjlNTjd0YWVZSGlQNTZQanFWQzF1UEZwcC1hZmRHcGJzRWFZNWlEVE94eGY2aGxGQi1oSlRPbktHUXZPSXNUaVkweF82YUpQVkpwYUFyYmRuZ0t1M1NJVDhmdG5sR01UZkN1cVNGZlJRdlN5aUcxWUR6Z0JETXpBNGMzN1A2TTBBTzY4RTBiQUl3ZkVROTBxLUJRT0lsS2M?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-13T07:00:00+00:00", "published_display": "13 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma lines up March health-care investor talks in Boston and Miami", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWUh4N08xQ0k3bUQwUW1uQ3JFa2dPSFFPX2FnNGl4bHVuaUo2YmUzOVpqd2JzRUF0RXhYY2Z3azM2ZUp1NW8yck8teEVadnFQb25RVTNkdWUtRWRoUlZkUEtyNXhtMWJNdGZFOFh5VUE4Z21xQUJiRVdtbndsZ1JzUmQyOVN0MU9wYnZYejZzeFhLTlI2VjJvem1FNF9Ublg4TmZfUmJWQTRDUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Oncology company Sutro lines up $110M for research and development", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPSW5JSVc0Zk1pTEdXZlpTc2RlU2xsRGFCVC10MGhwU2ZHQ1luYlZ3M2YxSkxHbURjTXZtb21mQUdlZ1pMNi1UY0llN3dHMjUzTEZqZ0g1WXlBR05XRG45TDlmOUlTd0pjOXVqLVBoVVZ0TlJpUHJDVnNISmVMS3VXbXZPUFh3aDNLYTJrWm11NXRydmZvSTVOQjlsS0hiN3haUDRNS3FJVGpPVHU3aHpnN1FFZE0zWU10M2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxQMEFUNkFidk9SWUF2X0QzYUtSTF84bV8tdUJ0QkowUi1IWDVKbVp0Q3otQWo5RXA1SFJ6bkU5Z2EzMkZCYWFnN1RBZjFLVXpXdm5UaW4yQUd0T2tpa1p4M19PTlhpcDQ5Um9OWU1GMHFlbXl1R0tDN1VCUlJUYmtDQlJZdw?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 67, "sentiment_summary": {"positive": 27, "negative": 7, "neutral": 33, "score": 57, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 17.2, "count": 30}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "analyst", "label": "Analyst action", "weight": 7.15, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 27, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 29.73, "latest_week": "2026-07-10", "one_week_move": -2.3, "four_week_move": 3.2, "twelve_week_move": -5.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.31097, "market_dynamics_buy_signal": false, "relative_strength": 50.127146, "fair_value_gap": 13.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 58.6538, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +3.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 9}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "MT Newswires", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "Moomoo", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 30}, {"label": "Earnings", "count": 18}, {"label": "Analyst action", "count": 13}, {"label": "Balance sheet", "count": 3}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.3% over one week, +3.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Sutro Biopharma, Inc. Common Stock (STRO) Stock Price Today: $26.03"}], "updated_at": "2026-07-16T08:07:31.673518+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}